Blood‑Brain Barrier Transport Mechanisms in Neurodegeneration: A Comprehensive Review
Blood‑Brain Barrier Transport Mechanisms in Neurodegeneration: A Comprehensive Review describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. @moos2000]
The blood‑brain barrier (BBB) is a dynamic interface that safeguards the central nervous system-regions/central-nervous-system) (central nervous system-regions/central-nervous-system)) while simultaneously mediating the flux of nutrients, ions, hormones, and therapeutics. In neurodegenerative such as Alzheimer’s disease (Alzheimer's disease) and Parkinson’s disease (Parkinson's disease), the BBB undergoes structural and functional alterations that contribute to disease progression. Understanding the molecular pathways that govern BBB transport—including receptor‑mediated transcytosis (receptor-mediated transcytosis), carrier‑mediated transport (CMT), active efflux via ATP‑binding cassette (ABC) transporters, and adsorptive‑mediated endocytosis (AME)—is essential for developing strategies that either restore barrier integrity or enhance drug delivery to the brain. This review synthesises recent insights into BBB biology, the role of ABC and solute‑carrier (SLC) transporters, and how these systems are perturbed in Alzheimer's disease and Parkinson's disease. Emphasis is placed on “Trojan‑horse” delivery platforms, emerging nanocarrier technologies, and the challenges that still impede effective central nervous system pharmacotherapy. [@duffy1987]
Keywords: blood‑brain barrier, neurodegeneration, receptor‑mediated transcytosis, ABC transporters, SLC transporters, Alzheimer’s disease, Parkinson’s disease, Trojan‑horse delivery, focused ultrasound [@ohtsuki2002]
--- [@simpson2001]
The BBB is not a single cellular layer but a neurovascular unit (NVU) composed of endothelial cells of the brain microvasculature, pericytes, astrocytes end‑feet, neurons, and microglia (Abbott et al., 2006; Zlokovic, 2008). Tight junctions (TJs) between endothelial cells restrict paracellular diffusion of water‑soluble molecules larger than ~400 Da, while theluminal and abluminal membranes host a rich repertoire of transporters and receptors that regulate trans‑cellular flux (Daneman & Prat, 2015). The endothelial glycocalyx and basal lamina further contribute to the barrier’s selective permeability (Nitta et al., 2003). [@broer2005]
In the healthy brain, the NVU maintains: [@schinkel1999]
BBB breakdown is a hallmark of many neurodegenerative disorders. Leakage of plasma , loss of TJ integrity, and altered transporter expression have been documented in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (Tajes et al., 2014). The resulting “neurovascular unit failure” compromises neuronal metabolism, promotes neuroinflammation, and limits the efficacy of central nervous system-regions/central-nervous-system)‑acting drugs (Zlokovic, 2008). Consequently, restoring or circumventing BBB transport has become a central research focus. [@loo2000]
--- [@stouch2005]
receptor-mediated transcytosis enables large molecules (e.g., peptides, antibodies, viral vectors) to cross the BBB by engaging specific receptors on the luminal membrane, undergoing internalisation into clathrin‑coated vesicles, and then being released at the abluminal side. The most extensively studied receptor-mediated transcytosis systems involve the transferrin receptor (TfR) and the insulin receptor (IR) (Pardridge, 1999; Zhang et al., 2004). [@asakura2005]
receptor-mediated transcytosis efficiency is governed by receptor density, internalisation kinetics, and the presence of endogenous competitors. Moreover, receptor saturation can limit delivery, necessitating careful dosing strategies (Bickel, 2005). [@nakanishi2013]
CMT employs solute‑carrier (SLC) that facilitate the bidirectional, saturable flux of small molecules (e.g., glucose, amino acids, nucleosides). Because CMT is driven by concentration gradients, it is particularly relevant for nutrient delivery and for the brain entry of essential drugs (Ohtsuki et al., 2002). [@borst2000]
Because CMT is limited by the affinity and capacity of each transporter, rational design of substrate‑based drugs can improve brain penetration. [@leslie2005]
ATP‑binding cassette (ABC) transporters use the energy of ATP hydrolysis to extrude a wide array of substrates, including many therapeutic agents. Their activity constitutes the single biggest obstacle to central nervous system-regions/central-nervous-system) drug delivery (Schinkel, 1999). [@gromek2022]
Collectively, these ABC transporters create a “chemical firewall” that limits brain exposure to potentially neurotoxic compounds but also hampers therapeutic efficacy. [@patching2015]
AME is a non‑specific, charge‑dependent process in which cationic peptides (e.g., poly‑lysine, HIV‑Tat) interact with the negatively charged endothelial membrane, leading to internalisation. While less selective than receptor-mediated transcytosis, AME can be exploited to deliver positively charged drug‑loaded nanoparticles (Gabathuler, 2010). [@broer2015]
--- [@akanuma2016]
P‑gp substrates include many psychotropic drugs (e.g., amitriptyline, fluoxetine), antiepileptics (e.g., phenytoin), and chemotherapeutics (e.g., paclitaxel). Its overexpression on brain endothelial cells is a primary determinant of multidrug resistance in neuro‑oncology (Stouch & Oprea, 2005). [@van2020]
Genetic polymorphisms in ABCB1 correlate with altered central nervous system-regions/central-nervous-system) distribution of certain drugs (e.g., the C3435T variant affects P‑gp expression). Moreover, chronic exposure to substrates can induce P‑gp expression, further limiting therapy (Schinkel, 1999). [@yan1995]
BCRP is particularly important for the efflux of bulky, lipophilic anions. Its localisation at the BBB is less dense than P‑gp, yet it significantly restricts the brain uptake of flavopiridol, methotrexate, and several tyrosine‑kinase inhibitors (Asakura et al., 2005; Nakanishi et al., 2013). [@shibata2000]
MRP1 (ABCC1) and MRP4 (ABCC4) mediate export of conjugated metabolites and organic anions. Their contribution to drug resistance is especially notable for antiviral nucleoside analogues and certain non‑steroidal anti‑inflammatory drugs (Borst et al., 2000; Leslie et al., 2005). [@deane2003]
In Alzheimer's disease and Parkinson's disease, altered expression of P‑gp, BCRP, and MRPs has been reported. Decreased P‑gp activity at the BBB correlates with accumulation of amyloid‑β (Aβ) in animal models, suggesting a role for efflux transporters in Aβ clearance (Gromek et al., 2022). Conversely, up‑regulation of efflux pumps in reactive astrocytes may limit the brain penetration of promising neuroprotective agents, necessitating the development of pump inhibitors or bypass strategies (Miller et al., 2015). [@zlokovic2000]
--- [@sengillo2013]
GLUT1 is the principal glucose transporter, with expression levels directly linked to cerebral metabolic rate (CMR). Its deficiency leads to severe neurodevelopmental deficits, while reduced GLUT1 availability in aging contributes to hippocampal hypometabolism in early Alzheimer's disease (Simpson et al., 2001). [@iadecola2004]
LAT1 forms a heterodimeric complex with 4F2hc (SLC3A2) and transports large neutral amino acids. LAT1 expression on brain endothelial cells is up‑regulated in response to increased neuronal demand, but its activity is compromised by Aβ‑induced oxidative stress (Broer et al., 2015). LAT1 is also a gateway for L‑DOPA, the dopamine precursor used in Parkinson's disease therapy (Akanuma et al., 2016). [@van2016]
Understanding the substrate specificity of these transporters enables rational design of “brain‑targeted” prodrugs that exploit endogenous uptake pathways. [@zlokovic2011]
--- [@chen2020]
Two-directional transport of Aβ is mediated by receptors: [@sotorosales2019]
Pericytes are essential for BBB integrity; their loss leads to compromised TJ scaffolding, increased paracellular leakage, and reduced capillary coverage (Sengillo et al., 2013). In Alzheimer's disease, pericyte degeneration precedes neuron loss and correlates with the deposition of vascular amyloid (amyloid angiopathy). The resulting neurovascular uncoupling diminishes CBF responsiveness to neuronal activity, further accelerating cognitive decline (Iadecola, 2004; van de Haar et al., 2016). [@kortekaas2005]
Neurovascular coupling (NVC) links synaptic activity to rapid increases in CBF through signalling pathways involving astrocytes, pericytes, and endothelial nitric oxide (NO) production. In Alzheimer's disease, Aβ‑induced oxidative stress and pericyte dysfunction blunt NVC, leading to hypoperfusion and a permissive environment for neurodegeneration (Zlokovic, 2011). [@fowler2022]
Restoring BBB function in Alzheimer's disease includes: [@pardridge2006]
--- [@gao2020]
Parkinson's disease is increasingly recognised as a “vascular” disorder. Neuroimaging studies reveal reduced CBF in the basal ganglia and frontal cortex, while post‑mortem analyses demonstrate endothelial cell degeneration and fragmented TJ strands (Kortekaas et al., 2005). Elevated plasma levels of matrix metalloproteinase‑9 (MMP‑9) in Parkinson's disease patients correlate with BBB leakage, suggesting enzymatic degradation of TJ (Chen et al., 2020). [@shilo2014]
Extracellular α‑synuclein (α‑syn) can traffic across the BBB via LRP1‑mediated transcytosis (Soto‑Rosales et al., 2019). Conversely, RAGE may mediate the uptake of circulating α‑syn, propagating seed‑propagation in the brain. The balance between efflux (LRP1) and influx (RAGE) likely dictates the rate of Lewy body formation. [@kreuter2014]
Microglial activation and pro‑inflammatory cytokines (IL‑1β, TNF‑α) released in Parkinson's disease compromise BBB integrity by down‑regulating claudin‑5 and up‑regulating adhesion molecules (VCAM‑1) that facilitate leukocyte infiltration (Fowler et al., 2022). Chronic neuroinflammation thus creates a feedback loop: BBB leakiness permits peripheral immune cells to infiltrate, amplifying neurodegeneration. [@chen2021]
Strategies targeting Parkinson's disease‑related BBB alterations include: [@nance2014]
--- [@hynynen2007]
The “Trojan horse” concept, pioneered by Pardridge, exploits endogenous receptor-mediated transcytosis pathways by fusing a therapeutic peptide or protein to a ligand that binds a BBB receptor (Pardridge, 2006). [@miller2015]
Nanocarriers can be engineered to exploit both receptor-mediated transcytosis and AME while protecting cargo from peripheral degradation (Gao et al., 2020). [@cook2014]
Emerging targets include the low‑density lipoprotein receptor‑related protein 1 (LRP1), the dipeptide transporter (PepT1), and the nicotinic acetylcholine receptor (nAChR) (Nance et al., 2014). Combining multiple targeting ligands can increase specificity and overcome saturation. [@kiviskk2003]
Focused ultrasound (FUS) combined with microbubbles transiently disrupts TJ integrity, creating reversible “windows” for drug entry (Hynynen et al., 2007; Cook et al., 2014). FUS has been used to enhance delivery of monoclonal antibodies, adeno‑associated viruses (AAVs), and chemotherapeutics in preclinical models of Alzheimer's disease and Parkinson's disease. Ongoing clinical trials are evaluating safety and cognitive outcomes in early Alzheimer's disease patients (Nance et al., 2014). [@thorne2008]
--- [@gaillard2015]
The historic “rule of thumb” that only molecules <400–500 Da can passively diffuse across the BBB is being challenged. Active transport and nanocarrier strategies have enabled delivery of larger biologics, but achieving therapeutically relevant brain concentrations remains difficult (de Boer & Gaillard, 2007). [@de2007]
Inhibiting P‑gp and BCRP can dramatically increase brain concentrations of substrate drugs (e.g., paclitaxel, doxorubicin). However, systemic inhibition leads to unacceptable toxicity in peripheral organs. Third‑generation inhibitors (tariquidar, zosuquidar) are being re‑evaluated in central nervous system-regions/central-nervous-system)‑targeted formulations that achieve local inhibition at the BBB (Miller et al., 2015). [@gromek2022a]
FUS-mediated opening can be combined with efflux inhibitors to further increase brain exposure. In a murine model of Alzheimer's disease, FUS combined with a P‑gp inhibitor resulted in a five‑fold increase in cortical concentrations of an anti‑Aβ antibody (Nance et al., 2014).
Measurement of BBB permeability via dynamic contrast‑enhanced MRI (DCE‑MRI) or cerebrospinal fluid (CSF)/plasma albumin ratios can guide patient selection for BBB‑opening strategies (Kivisäkk et al., 2003). Such biomarker‑driven approaches enable personalized dosing and reduce off‑target effects.
The blood‑brain barrier remains both the central nervous system-regions/central-nervous-system)’s greatest protector and the principal obstacle to pharmacotherapy for neurodegeneration. Over the past two decades, a detailed understanding of the molecular architecture of the NVU, the spectrum of BBB transporters (ABC, SLC), and the by which Aβ and α‑synuclein traverse the barrier has opened therapeutic windows. Strategies that either restore barrier integrity (e.g., pericyte‑supportive therapies, RAGE antagonists) or transiently bypass it (Trojan‑horse conjugates, FUS, nanocarriers) are advancing from preclinical proof‑of‑concept to early‑phase clinical trials.
However, several critical questions remain:
Addressing these challenges will demand multidisciplinary collaboration among neuroscientists, pharmacologists, bioengineers, and clinicians. The ultimate goal—an effective, disease‑modifying therapy that can be delivered safely to the brain—remains within reach, provided we continue to elucidate and manipulate the intricate transport that define the blood‑brain barrier in neurodegeneration.